echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Chuangsheng Group released the extended cohort safety and efficacy data for the first-line treatment of gastric cancer in the form factor of Osemitamab combined with chemotherapy at the 2022 ESMO Annual Meeting press release

    Chuangsheng Group released the extended cohort safety and efficacy data for the first-line treatment of gastric cancer in the form factor of Osemitamab combined with chemotherapy at the 2022 ESMO Annual Meeting press release

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    ● Interim data from the first 15 patients with measurable lesions who received TST001 (osemitamab) in combination with CAPOX as the first-line treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer showed that according to the RECIST 1.



    On September 13, 2022, Chuangsheng Group (06628.



    As of 4 August 2022, a total of 51 patients were enrolled and treated, including 36 patients



    All 51 enrolled patients underwent safety and tolerability assessments



    These data show that TST001 (osemitamab) combined with CAPOX is used for first-line treatment of Claudin18.




    Chemotherapy is still the mainstay of treatment for advanced or metastatic gastric cancer and gastroesophageal junction cancer, but its efficacy is limited



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.